Gilead announces licence and collaboration deal with Yuhan
10-01-2019
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25-07-2018
Avosb / iStockphoto.com
Germany’s Federal Patent Court (Bundespatentgericht, BpatG) has published the reasoning behind its decision to revoke Gilead Sciences’ supplementary protection certificate (SPC) for HIV/AIDS treatment Truvada,
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead Sciences, Truvada, Bundespatentgericht, patent infringement, HIV/AIDS treatment, supplementary protection certificate, basic patent, EU patent law
